The Role of Quantitative Measures on Dual-energy CT in the Prediction of Colorectal Adenocarcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Prospectively, 50 consecutive patients with pathology-proved colorectal tumor (detected by optical colonoscopy) who undergo routine thoraco-abdominal DECT for initial staging in the Department of Radiology at our institution from April 2020, will be included. The exclusion criteria are as follows: patients with body mass index (BMI) above 30 kg/m2, patients with renal insufficiency (estimated glomerular filtration rate < 30 ml/min), allergy to iodinated contrast and a known history of previous abdominal radiotherapy.
All patients will undergo a staging enhanced thoraco-abdominal CT by 256-slices CTs (Revolution CT, GE healthcare) at Fribourg hospital. DECTs will be acquired without an enema, rectal insufflation or oral contrast to have collapsed colorectal wall for further measurements and to simulate routine clinical practice. No additional screening procedures, such as a laboratory or diagnostic tests are necessary for the present study.
Upon acquiring 50 patients, CT quantitative assessments will be performed. Initially, data will be transferred to AW Advantage workstations (GE Healthcare). Thereafter, for each patient, the iodine map images will be created by post-processing by. All CT quantitative measurements will be performed independently by two radiologists. Three regions of interest (ROI) will be applied to colorectal tumor and the normal collapsed colorectal wall (confirmed previously by colonoscopy) and consequently, the mean of these measurements will be reported. These measurements correspond to mean iodine uptake of colorectal tumor and normal collapsed wall, respectively. Finally, the iodine uptake of the tumoral lesion and normal collapsed wall in each patient will be compared to demonstrate the significant difference in iodine uptake. Investigators anticipate that the obtained cut-off value will be a new benchmark in clinical practice, to exclude the colorectal tumors on non-prepared collapsed colon wall and eliminate the need for a complementary colonoscopy.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Fribourg, Switzerland, 1708
- Recruiting
- Sonaz Malekzadeh
-
Contact:
- Sonaz Malekzadeh, MD
- Phone Number: +41783012848
- Email: soonazmalakzadeh@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
. pathology-proved colorectal tumor
Exclusion Criteria:
- BMI above 30 kg/m2
- renal insufficiency (estimated glomerular filtration rate < 30 ml/min),
- allergy to iodinated contrast, and a
- known history of previous abdominal radiotherapy
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Colorectal adenocarcinoma
patients with pathology-proved colorectal tumor (detected by optical colonoscopy) who undergo routine thoraco-abdominal DECT for initial staging
|
No supplementary intervention will be applied
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference of iodine uptake
Time Frame: 3.11.2021
|
Difference of iodine uptake between colorectal tumor and pseudo-thickened colorectal wall on DECT
|
3.11.2021
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020-00052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Adenocarcinoma
-
NCT05200442SuspendedColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma
-
NCT06102902SuspendedMetastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Recurrent Colorectal Adenocarcinoma
-
NCT07147231RecruitingMetastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Adenocarcinoma
-
NCT07535112RecruitingAdvanced/Metastatic Colorectal Adenocarcinoma
-
NCT06696768RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Adenocarcinoma
-
NCT03699163CompletedColorectal Cancer | Colorectal Polyps | Colorectal Adenocarcinoma
-
NCT04017650Active, not recruitingProgressive Disease | Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8
-
NCT04729322Active, not recruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic Small Intestinal Adenocarcinoma | Stage IV Small Intestinal Adenocarcinoma AJCC v8
-
NCT05672316Active, not recruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma
-
NCT06195670Not yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC
Clinical Trials on No supplementary intervention is performed
-
NCT06410014RecruitingActivities of Daily Living | Muscle Strength | Disability Evaluation | Surveys and Questionnaires | Health Status | Physical Examination | ADL Motor Skills
-
NCT04872894CompletedFamilial Hypocalciuric Hypercalcemia
-
NCT02462616CompletedCardiovascular Autonomic Neuropathy
-
NCT03272854Active, not recruitingDiabetes | Death | Graft Failure | Death, Cardiac
-
NCT04928469CompletedCovid19 | SARS-CoV-2 Infection | COVID-19 Pneumonia
-
NCT01278732CompletedSuspected Arterial Hypertension
-
NCT05189249CompletedCoronary Artery Disease | Percutaneous Coronary Intervention
-
NCT02327052Completed
-
NCT06356233Not yet recruitingSTXBP1 Encephalopathy With Epilepsy